Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
This guide weighs PoW and PoS pros and cons, outlining scenarios where one may be preferable and what trade-offs to consider for a blockchain project.
21,439 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Two well-positioned tech companies could be the catalysts for a multi-year fortune-building journey. This guide break...
Three AI ETFS split starkly in early 2026: one climbs while another fades, illustrating how fund design shapes AI bet...
As crypto markets swing, STRC's flagship preferred shares are drawing more attention from everyday investors. This pi...
A geopolitical chokepoint isn't just about oil. The Strait of Hormuz also moves a vital portion of global fertilizer....
Ark Invest disclosed a new Alphabet stake, triggering debate over Google’s growth drivers and the broader tech rally....
If federal foreclosure protections vanish, the housing market could see a surge of distressed properties. This articl...
When the AI spotlight faded in April, some top names cooled off just enough to become bargains. This piece breaks dow...
Political rhetoric can shake markets and impact wallets. This article breaks down how trump’s “election integrity arm...
A quiet-upstart tech company just got upgraded by analysts after solid earnings. This under-the-radar growth stock ma...
Semiconductors have sprinted this year, but a cooling period is drawing attention. History suggests pauses can lead t...
Hyperliquid's AQAv2 upgrade pushes HYPE higher as Coinbase and Circle commit to the new stablecoin framework, alignin...